FRAMINGHAM, Mass., March 20 /PRNewswire/ -- Transport Pharmaceuticals, Inc., a leader in combination drug/medical devices for the topical treatment of dermatological conditions, today announced the expansion of its Scientific Advisory Board with the appointments of Bruce E. Strober, M.D., Ph.D., Agis Kydonieus, Ph.D., and Mark R. Prausnitz, Ph.D.
Dennis I. Goldberg, Ph.D., President and Chief Executive Officer of Transport commented on the appointments, "Transport welcomes Drs. Strober, Kydonieus and Prausnitz to our Scientific Advisory Board. Their guidance and expertise in drug development and delivery will be important to the company as we expand our clinical and development programs."
Dr. Goldberg continued, "In 2007, Transport is poised to enter late-stage development of our lead product, SoloVir(TM), for the treatment of herpes labialis. We are also advancing our product pipeline and intend to file an IND for a topical onychomycosis product later in the year. In addition, we will evaluate a number of promising clinical candidates for indications such as skin cancer, warts, acne and psoriasis."
Bruce E. Strober, M.D., Ph.D., is an Assistant Professor in the Ronald O. Perelman Department of Dermatology at New York University School of Medicine and Associate Director of the Dermatopharmacology Unit. Dr. Strober is a diplomat of the American Board of Dermatology, a fellow of the American Academy of Dermatology and a member of the Medical Board of the National Psoriasis Foundation. He is also Co-Director of the Psoriasis and Psoriatic Arthritis Center of New York University Medical Center and is involved with numerous clinical trials for the development of therapies for psoriasis, psoriatic arthritis and other dermatologic diseases.
Agis Kydonieus, Ph.D., is the President of Samos Pharmaceuticals, LLC, a company involved in consulting and development of drug delivery systems, biomaterials and medical devices. He is one of the Founders of the Controlled Release Society and formerly its President. He is a leader in drug delivery, especially in the field of transdermal delivery.
Mark R. Prausnitz, Ph.D., is the Professor of Chemical and Biomedical Engineering and the Emerson-Lewis Faculty Fellow at the Georgia Institute of Technology. Dr. Prausnitz has considerable experience using electric fields for drug delivery across skin and into cells by means of electroporation and iontophoresis. His research interests also include microneedles and other microfabricated devices for drug delivery across the skin and into the eye. Dr. Prausnitz also has considerable experience using ultrasound and related physical phenomena to enhance and target intracellular delivery.
The new additions to Transport's Scientific Advisory Board will join existing members, including Ajay K. Banga, Ph.D., Professor and Chair in the Department of Pharmaceutical Sciences at the College of Pharmacy and Health Sciences, Mercer University; Spotswood L. Spruance, M.D., Professor of Medicine in the Departments of Internal Medicine and Dermatology at the University of Utah School of Medicine; and Kuo-Wei Chang, Ph.D., Vice President of Industrial & Biomedical Sensors Corp.
About Transport Pharmaceuticals, Inc.
Transport is bringing together cutting-edge medical electronics with drug formulation and material sciences to develop drug/device combination products that enhance movement of drugs across the stratum corneum (the skin's outer layer) by means of electric current. Transport's lead product, the SoloVir(TM) electrokinetic transdermal system, utilizes the company's proprietary five-percent acyclovir gel-formulation to treat herpes labialis, or cold sores. Pharmacokinetic data from a recently completed Phase I study indicate that a single ten minute application of SoloVir(TM) delivered more than 100 times the published peak tissue levels (2 ug/ml) of acyclovir achieved with a 1 gram dose of Valtrex(R), a leading oral-antiviral drug marketed for the treatment of herpes labialis. In addition, the peak tissue levels are achieved at the time of administration with SoloVir(TM), while orally administered Valtrex(R) requires more than two hours to reach peak acyclovir levels in the skin.
Transport is a Massachusetts-based, privately-held specialty pharmaceutical company. Current venture investors include Quaker BioVentures, The Carlyle Group, The Hillman Company and The Halleran Company. For more information, please visit www.transportpharma.com.
Transport Pharmaceuticals, Inc.
CONTACT: investors, Sean Moran, Chief Financial Officer of TransportPharmaceuticals, Inc., +1-508-872-0433, email@example.com; ormedia, Bryan Murphy, Director of Public Relations, LaVoie Group,+1-978-745-4200 x105, firstname.lastname@example.org, for TransportPharmaceuticals, Inc.